ABOUT THE AUTHORS

Howard Guo, MD
Dr. Howard Guo is a gastroenterology fellow at the University of Calgary. He earned his medical degree from the University of Ottawa and subsequently completed his residency in internal medicine at the University of Calgary. Alongside clinical care, he also has a strong interest in medical education, and has been actively involved in gastroenterology clinical teaching and medical education projects at the University of Calgary.

Affiliations
Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary

Christian Turbide, MD
Dr. Christian Turbide graduated from McGill University in gastroenterology with specialty training in therapeutic endoscopy and endoscopic retrograde cholangiopancreatography (ERCP). He completed his fellowship in endoscopic ultrasound. Dr. Turbide has been an examiner at the Royal College of Physicians and Surgeons for internal medicine and gastroenterology and is the past recipient of the endoscopy teacher of the year and clinic educator of the year. He is also the past President of the Alberta Society of Gastroenterology.

Affiliations
Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary
DIAGNOSIS AND MANAGEMENT OF IRRITABLE BOWEL SYNDROME: A PRACTICAL OVERVIEW FOR PRIMARY CARE PROVIDERS

Introduction
Irritable bowel syndrome (IBS) is a common gastrointestinal (GI) disorder estimated to affect 10% of the Canadian population. Despite its high prevalence, IBS remains a challenging condition to diagnose and manage due to its varied clinical presentations. Patients with IBS often experience a range of distressing symptoms, including abdominal pain, bloating, disordered bowel habits and psychological distress, which significantly impact their quality of life (QOL). As a result, patients with IBS are more likely to be high-frequency medical consulters, leading to an increased burden on healthcare systems. This article aims to provide a practical overview of IBS, including its diagnostic criteria, workup and management strategies.

Clinical Presentation
IBS is considered a manifestation of bidirectional disordered communication within the brain-gut axis that influences GI motility, secretion and sensation. Contributing factors such as genetics, personality traits, alterations in stress-responsive physiologic systems, changes in the microbiota, and sequelae of enteric infections may also play a role in the pathogenesis of IBS. Due to its complexity, patients with IBS can present with a multitude of varying symptoms. The hallmark characteristic of IBS is recurrent abdominal pain with altered bowel habits. Bloating, nausea and dyspepsia may also be present, and can be seen in up to two-thirds of patients with IBS. In addition, IBS is correlated with other pain syndromes and, therefore, symptoms such as dysuria, widespread musculoskeletal pain, dysmenorrhea, fatigue, anxiety, depression, and headaches may be observed as well.

Diagnostic Criteria
The recommended diagnostic criteria for IBS are the Rome IV criteria, which were published in 2016:

- Recurrent abdominal pain, on average, at least one day per week in the last three months, associated with two or more of the following criteria:
  1. Related to defecation
  2. Associated with a change in frequency of stool
  3. Associated with a change in form (appearance) of stool

The Rome IV criteria represent a departure from the historic belief that IBS is a diagnosis of exclusion, and allow clinicians to make a positive diagnosis of IBS based on symptoms and limited testing. The Rome IV criteria also reflect some notable changes from the Rome III criteria, such as removing the term “discomfort” from the diagnostic criteria due to its ambiguity, and modifying the phrase “improvement with defecation” to “related to defecation” to better reflect the experiences of patients with IBS.

IBS Subtypes
IBS can be further classified into four subtypes based on the patient’s predominant bowel habits:

1. IBS with predominant constipation (IBS-C): More than 25% of bowel movements are Bristol stool form Types 1 or 2, and less than 25% of bowel movements with Bristol stool form Types 6 or 7.
2. IBS with predominant diarrhea (IBS-D): More than 25% of bowel movements are Bristol stool form Types 6 or 7, and less than 25% of bowel movements with Bristol stool form Types 1 or 2.
3. IBS with mixed bowel habits (IBS-M): more than 25% of bowel movements with Bristol stool form Types 1 or 2, and more than 25% of bowel movements with Bristol stool form Types 6 or 7.
4. IBS unclassified (IBS-U): Patients who meet the diagnostic criteria for IBS, but whose bowel habits cannot be accurately categorized into the above three groups.

It is important to recognize that IBS subtypes can only be established when patients are evaluated in the absence of any medications that can affect bowel habits. The prevalence of IBS-C, IBS-D, IBS-M, and IBS-U are 20.0%, 27.8%, 33.8%, and 14.1% respectively.

IBS Workup
The diagnosis of IBS requires a comprehensive medical history, physical examination and limited diagnostic tests. Clinicians should take a thorough medical history to understand the frequency, severity and localization of a patient’s abdominal pain. It is also important to identify whether or not a patient has a history of disordered bowel habits and to determine the temporal association with episodes of abdominal pain. IBS is a chronic pain disorder, and the presence of disordered bowel movements in the absence of abdominal pain is inconsistent with IBS. Identifying a patient’s predominant symptom (pain, constipation or diarrhea) is critical as it will impact treatment selection. Clinicians should carefully review the patient’s medication and diet to identify triggers that may mimic or exacerbate IBS symptoms. A brief
The CAG recommends offering IBS patients a low FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, polyols) diet based on evidence from four randomized controlled trials (RCTs) demonstrating its efficacy. Increased dietary intake of soluble fibre (such as psyllium) also has a significant effect on the treatment of IBS symptoms.

Probiotics should be offered to patients with IBS, as clinical studies have shown the superior efficacy of combination probiotics vs placebo. However, there is significant heterogeneity between studies and insufficient evidence to support any particular species of probiotics.

In contrast, a systematic review of three eligible RCTs failed to demonstrate any clear benefit of prebiotics in the treatment of IBS. In addition to these interventions, the CAG recommends considering peppermint oil, cognitive-behavioral therapy (CBT) and hypnotherapy as alternative treatment options for IBS patients.

**Treatment of Abdominal Pain in IBS**

It is important to consider that while disordered bowel movements can be treated with medications, IBS is a chronic pain disorder and clinicians should place an equal emphasis on treating patients’ pain. Antispasmodics, low-dose tricyclic antidepressants (TCAs), and selective serotonin receptor inhibitors (SSRIs) are commonly used to treat abdominal pain in IBS. In Canada, the three available antispasmodics with proven efficacy are hyoscine, pinaverium and dicyclomine. However, the evidence for their effectiveness is generally weak, and there is a potential for anticholinergic side effects. Peppermint oil also has antispasmodic properties and, although the evidence is of low quality, it should be offered to patients with abdominal pain (Table 1).

TCAs and SSRIs have good-quality evidence demonstrating efficacy in improving IBS-associated abdominal pain. TCAs, such as amitriptyline, desipramine, doxepin, imipramine, and trimipramine, are known to prolong gut transit times and can cause constipation. Therefore, they may be more effective in IBS-D. In contrast, SSRIs, including citalopram, fluoxetine and paroxetine, may decrease transit time and are preferred in IBS-C.

**Treatment of IBS-D**

Loperamide is a μ-opioid receptor agonist that decreases colonic transit and can be used to treat diarrhea. However, its prolonged use should be avoided as it may lead to constipation. Loperamide may be beneficial in patients with IBS-D as a prophylactic or as-needed treatment before social situations or travel. It is important to recognize that while loperamide is effective in treating diarrhea, it does not improve other IBS symptoms such as abdominal pain. Eluxadoline is a synthetic opioid receptor modulator approved by Health Canada in 2017 for the treatment of IBS-D and has demonstrated moderate-quality evidence of efficacy. However, it is contraindicated...
in patients with biliary duct obstruction, cholecystectomy, pancreatitis, and hepatic impairment. Clinicians should carefully consider the potential risks of eluxadoline before prescribing it to patients with IBS-D. There is also emerging evidence supporting the use of rifaximin, a non-systemic antibiotic, in managing IBS-D. A 14-day course of rifaximin has demonstrated moderate-quality evidence of efficacy in reducing symptoms. Additionally, bile acid sequestrants have shown promise as a second-line treatment option for IBS-D options.

Eluxadoline and rifaximin are the two medications currently approved by Health Canada for the treatment of IBS-D (Table 1). In order for medications to be approved by Health Canada, they must improve both disordered bowel movements and abdominal pain.

### Treatment of IBS-C

The importance of adequate soluble fibre and water intake should be emphasized to all patients with IBS-C, alongside pharmacologic therapies. Polyethylene glycol is an osmotic laxative which has beneficial effects for constipation, but limited effects in treating other IBS symptoms. Linaclotide and plecanatide are guanylate cyclase-C agonists that are effective in improving both abdominal pain and diarrhea. Despite its relatively expensive cost, the CAG has made a strong recommendation in favour of using linaclotide in IBS-C patients. Similarly, lubiprostone is also recommended in the treatment of IBS-C, it is generally more expensive than similar medications. Tenapanor is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), which increases water secretion and accelerates intestinal transit. Tenapanor has been shown to have improved IBS-C symptoms in RCTs and is generally well tolerated by patients. Linaclotide, plecanatide, and tenapanor are the three medications currently approved by Health Canada for the treatment of IBS-C (Table 1).

### Treatment of IBS-M/U

Managing IBS-M and IBS-U can be challenging due to their sporadic and varying symptoms. In addition to pharmacologic therapies, dietary modifications and lifestyle principles are important in managing these subtypes of IBS. Efforts should be made to identify common food triggers and remove these from the patient’s diet. The use of a food diary and referral to a registered dietician can be helpful to support dietary changes. Soluble fibre supplementation and adherence to a low FODMAP diet should also be emphasized to patients.

Regular exercise is recommended for patients with IBS-M/U, as accumulating 150 minutes per week of aerobic physical activity has been shown to be an effective strategy for stress reduction. In addition, counselling and reassurance are key to long-term effective management of IBS-M/U, and referral for CBT should be considered.

Pharmacologic management of IBS-M/U is challenging.

---

**Table 1: Pharmacologic treatments for abdominal pain, IBS-D, and IBS-C.**

<table>
<thead>
<tr>
<th>Abdominal Pain</th>
<th>IBS-D</th>
<th>IBS-C</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hyoscine</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 10–20 mg TID</td>
<td>Loperamide</td>
<td>Polyethylene glycol</td>
</tr>
<tr>
<td>• Up to 60 mg/day</td>
<td>• 2–4 mg daily as needed</td>
<td>• 17 g daily as needed</td>
</tr>
<tr>
<td><strong>Pinaverium</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 50 mg TID</td>
<td>Eluxadoline*</td>
<td>Prucalopride</td>
</tr>
<tr>
<td>• Up to 100 mg TID</td>
<td>• 100 mg BID</td>
<td>• 2 mg daily</td>
</tr>
<tr>
<td><strong>Dicyclomine</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 20 mg QID</td>
<td>Rifaximin*</td>
<td>Linaclotide*</td>
</tr>
<tr>
<td>• 550 mg TID x 14 days</td>
<td>• 290 μg daily</td>
<td></td>
</tr>
<tr>
<td><strong>Peppermint oil</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 0.2 to 0.4 ml TID</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Amitriptyline</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 10–25 mg QHS</td>
<td></td>
<td>Lubiprostone</td>
</tr>
<tr>
<td>• Up to 100 mg/day</td>
<td>• 8 μg BID</td>
<td></td>
</tr>
<tr>
<td><strong>Citalopram</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 10–20 mg daily</td>
<td></td>
<td>Tenapanor*</td>
</tr>
<tr>
<td>• Up to 40 mg/day</td>
<td></td>
<td>• 50 mg BID</td>
</tr>
</tbody>
</table>

* Medications approved by Health Canada for the treatment of IBS.
due to the limited available evidence to guide treatment. Medications such as TCAs, secretagogues (lubiprostone, linaclotide) and antispasmodics are often used, but clinicians must remain aware of their potential side effects.

Conclusion
IBS is a highly prevalent and often debilitating GI disorder that affects a significant proportion of the Canadian population. In recent years, there have been significant advancements in our understanding of IBS, including the development of the Rome IV diagnostic criteria. These criteria help reduce unnecessary investigations and improve the subtyping of patients with IBS to better guide treatment. The management of IBS involves a multidisciplinary approach that includes dietary modifications, pharmacological and non-pharmacological interventions, and psychological support. This approach can be effective in reducing symptoms and improving the QOL of individuals with IBS.

Correspondence
Dr. Christian Turbide
Email: cturbide@UCalgary.ca

Financial Disclosures
Dr. Howard Guo has no conflicts of interest to declare. Dr. Christian Turbide has previously received speaking honoraria from Lupin Pharma and Bausch Health.

References
10. Dionne J, Ford AC, Yuan Y, Chey WD, Lacy BE, Saito YA, Quigley EM, Moayyedi P. A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAP diet in treating symptoms of irritable bowel syndrome. Am J Gastroenterol. 2018 Sep 1;113(9):1290-300. doi:10.1038/s41395-018-0195-4